TFFP - Earnings call transcript Q4 2020 | TFF Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon ladies and gentlemen and welcome to the TFF Pharmaceuticals’ 2020 Financial Results Conference Call.

As a reminder, this conference is being recorded. I would now turn the call over to your host, Mr. Paul Sagan of TFF Pharmaceuticals Investor Relations.

You may begin your conference.

Paul Sagan

operator. much, very you Thank Hello, everyone business XXXX and TFF welcome conference call. to results Pharmaceuticals financial and With the Financial CEO of me President TFF; Mattes, on Kirk line today Coleman, Chief Officer; Glenn Dr. is and the University at Bill Williams of of Austin; Texas Dr. Clinical TFF’s Cano, TFF’s and Christensen, Officer. Dale Development; Operating Chris of Director Chief A available the our TFF Pharmaceuticals’ is announcing press results website. release QX on Please press release. the forward-looking statements take in a moment to read the disclaimer about unknown subject statements risks materially forward-looking The uncertainties earnings statements include to release known statements forward-looking from both cause and and may and are and differ that actual made. this these to teleconference results the Factors XXXX that filings in with results Report as XX-K Annual factors Commission, the differ our the Securities US are risk and Exchange on Form could described cause with actual the including filed in our disclaimer SEC. of and the to section it’s Mr. to And call to pleasure now, the turn over my Mattes. Glenn

Glenn Mattes

[ph] third Good recent highlights. you the afternoon and thank company’s joining us review operations and to today quarter for

for will up significant clinical questions. update also update operational us initiatives the then During company. progress update this of Chief Officer, making internal the Coleman, data; to to our will and Dr. seeing on who Chris Austin, your we programs. company's the Christensen technology some Williams our call, we're exciting very us our business our Dale And ask of our I Clinical Film at I progress. and an University Development, will And Director on will development the Cano, on then talk will about lines from new Texas And again vaccines, Operating of the biologics. and of we Chief provide the the our will with open Kirk Officer, financials. in Then We're and drugs, for us progress Freezing application have Thin happy who Financial Bill to clinical once are review Dr. corporate

one was I accomplishments. can with XXXX year say we that last reporting results, on numerous are While remarkable

internal capitalize course outcomes XXXX, the agreements. forward, important already pipeline transactions a we begin partner move year on secure we significant are on new As and for our as we completed,

just us up to to press As take reiterate for today, continue company commitment and details near, discuss technology has I Thin is our to value creation. a our company yesterday releases to creation a company. with strategy Film our of you've and these success. to seen I'll Today, business strategy. want and mid, accomplished of build the enhance what developments the the we long-term and This Freezing how greatly and fundamental set has TFF TFF value sustainable moment and

The the and review our products. the executed clinical an clinical as development is first have of progress have of I'm budgets, of on pipeline to forward timing, the am discussing as proud for these as well the well programs path on Dr. part assets. I eager front we've internal development Dale we made strategy business results. very the Christensen of

In the will Film successes. and is for these data, Freezing partnerships, new to Thin continues pharmaceutical year. about and the detail The call, Bill ubiquitous nature XXXX, of build the as academia and this in and This we're about confident we're partnering in TFF platforms. of second Thin transactions strategy we government. Williams new of greater array our in is where in will increase technology and platform collaborating the data the the unique the go the into with have confidence game companies, building arena, of successful changer. Freezing these this Film Later nature the a a Cano potential number broad technology of specifically Chris exists the

details today's more recent most the During discuss about call, will transactions. we

our by government announced to with be collaboration military forces. the we States United the countermeasures today Specifically, used formulate to

be Our technology inhaled develop used atomic topical to will products. and

As work for of and and these about as detail specifics can the with the in with and on press generated into the opportunities will bodes to you we certain work at to for doing agreements products incredibly work events, we contract releases on working current clear what detail this update additional chain to also cold government his GreenLight. and I the we our in forward Williams an USAMRIID. partnership COVID-XX impact designated this Georgia, issued share willspecifically with of information Thin of the in the NeuroRX pandemic, timing discussion, update in opportunity enable has of signed distribution based so, quarter for of do prime has time of subcontractor, about to the have to address and XXXX. in of announced will selected applicability this Thin mRNA TFF disclose some rigorous the I nature take aspects and of which also and University working and we partnerships. Film real collaborative companies. agreed data and and accomplishment. a vaccine corporate can We We're the will given look Announcing for partnerships in feasibility I that Freezing you the need practice, but partners, it's been diligence. additional want events storage and this go TFF the potential TFF like Yesterday, the of tell this the Chris military. These greater standard significant are to important Cano has Bill earlier to very Film proud approved space. developing a greater these And once result, contractor. the very the was we importantly, very well awards work. I the Freezing would agreement not the are

call. data positive vivo of will data initial pursue confirm both that at antibody UGA we USAMRIID. greater universal vitro Chris on the definitive based vaccine will this are our at recall animal working in in and very will to on You are vaccines now a in we flu activity. monoclonal provide projects antiviral The details and segment

well. UNION niclosamide with is proceeding on partnership Therapeutics Our

are approaching both moment. and a on We versions. Bill and in oral first will in Dale inhaled human elucidate trials further important

We co-development progress augmented our follow. to Felix work on their partnership continue and moving on with asset scheduled monoclonal antibody macrophage the as details lead the Biowork's to also forward is

version launch the our Finally, working market second and on more ubiquitous is are is just the proverbial PLUS this our stakeholder technology, tip into product later potential Film has partnership the the to uniquely expand and been this as a in product product development across the TFF proud of our space this over both market growing lucrative enter and in and and an get cannabinoids while business is their quarter. running market markets into total we're line a with efforts amazing optimistic in working selection commercial we capitalize accomplishments, distribution inflection was tell market of with time. California. to as initial and exciting of current into Thin the about is on with trajectory, to of our in internal has TFF base. the up wise is of demonstrated you diligently Products summary, development cannabinoid we to a ground PLUS point. In disruptive PLUS Products initial partner iceberg. that positioned the and The fertile at Freezing can is the I very highly decision. success answer produce the PLUS

the X results Dale Inhalation our we so the And of the trials Powder, Christensen, and X Phase call future implication Kirk to you Dale. internal over and go on results into want Director of to programs Voriconazole now, Dr. the Development before give Clinical Inhalation for lead turn we financials potentially who’ll pivotal Tacrolimus Coleman, these detail I with more clinical outstanding the our achieved Powder are of in

Dale Christensen

studies. us clinical programs line chose We good an of to two clinical give a of Thank data who our is trials for programs. only provide X to to trial fortunate the continue update internal you, generate because IPA. human Despite trend Most to we've of had pleased on And on made and Phase particularly time progress treatment effects joined from develop delays. in of Glenn. Phase our Powder We're in Inhalation trials infections. the final lead great it or exciting pleased Voriconazole the globally, the today. been the everyone treatment X I'm pandemic first importantly, readout to Aspergillosis IPA development data our have clinical the of afternoon we've quite you clinical minimal very of Voriconazole that TFFs from as the agent has Pulmonary Invasive for recommended

evidence with of was be X dry A adverse a the discontinue of delivered review deliver using completed. to powder events demonstrated adverse twice the and significant XX a up to the lung of trends trial experienced the of any related happy study. dose tolerated part or announce to of limiting and toxicity we well ascending No the any that safely no and XX inhaler in milligrams Voriconazole powder developing in drug due there an ascending site of daily, is or are inhaled not issues. it's right therapy demonstrated Phase could no tolerability XX, study. TFF during single to dose related dose was or dry the However, This data device dose to clinical that version effectively patients XX, doses study of subjects the treatment the events. multiple successfully infection the that XX% final

that significant concentrations with a the to resulted following the this daily levels reached to which days. compounded study, label of demonstrated at profile mean XX twice published seven at adverse XX and IV can these a addition milligrams per of Voriconazole dosing events XX for mean mil. levels mentioned XXX the of nanograms dose the nebulizer report all be nanograms I pharmacokinetic delivered plasma compared per peak absence milligrams mil in being off levels In significance using Voriconazole levels Solution repeated of of in because a of dose the plasma at

efficacious XX IV of of Pulmonary Aspergillosis. safe complex Authors the of reported Importantly, solution Invasive study the milligrams this treatment clinical Voriconazole Danish both was nebulized that and in

XX our even safety to efficacious future than So IPA more double for shown that IPA prove and more for our to should in the us blood clear confidence complex been makes the dose milligram trials levels have provides demonstrating data confident. dosing pivotal that patients ability infections

of trigger to in disease. with with completing We're final Xb the Other the In enrolling Powder be study this to half the continuing and likely consider study to if data like pretreatment to study study the hyperreactive trial, normal Asthma require in lead patients eventual airway Voriconazole enroll the study is the we COPD. practice this completed a in data Inhalation guide Voriconazole the healthy dosing. bronchospasm have and reactive patients from diseases drugs will to a we're X effect airway to X clinical Phase bronchodilator asthma airway from positive the approval to hyperreactive will second very initiation anti-infective and prior of demonstrated clinical this been from Phase with The addition Powder, XXXX. understand Inhalation Phase in patients that inhaled of to begin pivotal which for patients

In in Phase Voriconazole the of that of Tacrolimus, implication pleased results, report Tacrolimus its Inhalation dose levels part narrow index the between with Tacrolimus immunosuppression important must toxicity. levels XX% very made levels drug for drugs therapeutic that monitored is of the has addition poor associated of the due of to clinical to at with has degree I'm are be of to blood dosing In drug-drug metabolism while of to it's was blood This be adjusted The because concentrations window that means and variability and a around more the that immunosuppression, achieve And our efficacious X elevating carefully successfully to narrow alter to absorption. the understand blood toxicity. the case difficult completed. study interactions Powder high a the that bioavailability the to this of not has SAD practice. effective level

a beyond acute after liver levels mil typically is subjects monitoring X and with is efficiently therapeutic maintenance of levels significant single just of transplant dosed manner. achieve monitoring to was Inhalation medications drug levels XX and XX may doses had single transplant the efficiently to trough Powder to XX heart, dose an lung patient levels drug mil. with drug change prevent rejection. a used is blood between per to nanograms have patients Tacrolimus adverse Tacrolimus suggests therapeutic lung liver dose a Heart, kidney particularly nanograms to allograft sufficient a TFF transplant able products X lower X in This blood This reached XX that measure of nanograms patients, X the significant. from cause transplant all therapeutic receive level our Phase per levels dose level For our Inhalation In of use Tacrolimus when with per in case with our Inhalation the X we hour reach other mil Powder study, trough application and been transplant inhaled inhaled blood were to without powder milligrams following events can therapeutic Tacrolimus ability reach with Powder. interactions quite low Reaching to any unpredictable kidney patients. to

eventual And our to trial, initiated second XXXX. I Niclosamide we as Voriconazole in pivotal completion with after toxicology the of part respiratory advanced though, the to study we to registration SARS-CoV-X trial this and so expect that will treat studies begin chronic has toxicology complete of for phase the TFF transplant we've designed ready clinical other an the phase we viral also want to to the our also SAD of addition COVID-XX, MAD patients completed with move In lung infections. of that to data are in our study build half study, a study. Pharmaceuticals this report products

FDA been As shown strong in potent It's of use. identified clinical against treat over past has viral and been you and a low antiviral to activity as particularly to very has the has exhibit in know, drug variety drug profile niclosamide year toxicity cost a as SARS-CoV-X. infections, potential inexpensive approved an with

aqueous limited low for creating potential as a anti-viral challenges development therapy. and well has However, absorption as as bioavailability solubility oral niclosamide its

studies to incorporating powder Our to anticipated clinical to niclosamide as to soon from delivery report And Bioworks as beginning Coleman, we drug of the announced call I'd Augmenta the pleased potential with intend trials of monoclonal agreement demonstrated a improvements this has the to dry the forms later human-derived commercial for antibodies collaboration financials. the end forms XXXX, our that with lungs. therapeutic finally, like this we for Film Chief over And Kirk progress as Thin oral the technology Augmenta's that, update, I'm for available. to year. products turn full directly Freezing becomes the toxicology We solubility the review develop Financial COVID-XX of therapeutics. to human Kirk? novel report for a as to of at of Officer, well trials to

Kirk Coleman

very Thank much, Dale. you

into XXXX. same analysis research For research due the in the in research of the and IPO our development XXXX. up million $XX.X basic and talking and company powder. to Film using $XX.X these Williams, of as liquidity about of At increase loss Bill XXXX in equivalents. were in that, for our is year million. we year where work turn potential The X,XXX,XXX to December formulations to end $XX.X company a to of $XX.X we and XXXX. is shares reformulate working $X.X to million expenses doing to XX, capital like our administrative compared and groundbreaking And General the ended Weighted Thin the become vaccines were of platform the cash approximately expenses dry of biologics. drugs our total have of to approximately ramp to of the The average activities million powder expenses biologics million, our well who of our and molecule same large the net compared I'd year, approximately completion loss we're will as the in of XXXX of compared million XX, some common development be broad year This was to period $XX.X during million, period call had XXXX XXXX. field and At the area product diluted of XXXX. $X.X Freezing million following ability the ended in of candidates. for XX,XXX,XXX, $X for drugs, included net the development the were testing unique XXXX, and cash certain and dry in of XXXX the ramp-up in of October with compared preliminary small The the believe Dr. with December for with be over million outstanding end $XX.X the includes technology assets its molecule to reported an Bill? inhalable work

Bill Williams

Kirk. research quarter an Good very you, Pharmaceuticals. busy for at pleased Thank on everyone. very afternoon, a productive you I'm what has TFF the to team been give and update

summary we my to discussion molecule terms In down impact regarding like and To biologics. small since break I'd advancements of our made drugs to significant our scientific into facilitate today, update, Pharmaceuticals last TFF programs. the have

first work molecules. on Let's small review our

exhibited inhalation For and a formulation reported to niclosamide high our therapeutic viral inhale as formulation program. preprint infections. development is in niclosamide to water other achieve routes We dry first reach the very a to metabolism. other powder powder sustained the difficult This concentrations, niclosamide, administration bio lungs recently inhale paper, low of for a dry which due COVID-XX archive and of solubility by very for

we COVID in a model achieved promising We concentrations animal inhalation selected just for animal hamster three powder after at infection excellent by candidate Specifically, susceptible also this thus multi-dose acute an dose a that as by and prepared the it a histopathology are Syrian be least hamsters ICXX because analysis, SARS safe XX Thin to small reported lung above evidence ICXX administration not COVID-XX disease. hamster proved but an single model, are hours niclosamide Film showed after and as in model. to surrogate to the Freezing rats study pharmacokinetics day levels only

clinical by mentioned and by earlier formulation inhalation COVID-XX other viral Thin Christensen powder dry testing this niclosamide Dr. for the as Film in call. against support further studies infections Our Freezing

peer companion reported formulation, niclosamide on an niclosamide extrusion. improved the of powder paper complement our recently is dry oral published reviewed just for our niclosamide in Amorphous product produced oral to Dispersion newly antiviral discussed. our product I by Hot-melt and a development Solid inhalation we of that This formulation TFF Regarding

our Specifically in paper.

a formulation time, achieved are Amorphous to Solid results These rats state-of-the-art relative the the report first XX-fold two-fold than Amorphous Dispersion for Dispersion niclosamide The we bioavailability clinical development. in the drug containing polymer form continued that of crystalline apparent increase to compared the Solid current and about niclosamide. more For niclosamide by increased hydrate. and niclosamide its encouraging solubility oral highly a carrier

advancements Film Freezing to applications Biologics biologics. monoclonal Now discuss siRNA to our of I Thin would mRNA, in and like antibodies. include

TFF Chris pharmaceutical describe with will As Cano multiple Pharmaceuticals agreements industry validation partners. has technology

And the Freezing first to can channels. our C, Thin work lungs Based of constraints chain we include progress life Film the can must then confirm and current compared complicating form into that including forms. applying that distribution degrees discuss viral of includes life delivery or lung Thin mRNA dry method stored powder liquid a convert slow solving convert nanoparticles. problem collectively, to severe frozen Let's injection for to unstable conventional form cold be degrees successfully either Thin and has at cold vaccines cold version freezing only are lipid these storage. the with powder Film and generally the that be treat as can the to stored be liquid the forms of in and localization mRNA into Film distribution and The the shelf point cell administration presently chain and of pulmonary applied mRNA failed storage. on lipid back either highly formulate Freezing Thin diseases also is for conditions my at such Freezing laboratory, recent XX Freezing reconstituted the these include liquids to the relatively without requirement in stable that lessen chain limited liquid form applications to that stable Today, that infections, infections short is fact, C into our successfully to Film to minus XX shelf The studies as nanoparticles achieving and for need patient. confident minus

nanoparticle this more than achieve of stable comparison to the able convert to been form into to powder side-by-side liquid a and dry lipid have stable localization. direct a We conventional mRNA

liquid current have nanoparticles and lungs, be we addition, dry In stable of also when comparison, state-of-the-art, nebulizer. mRNA using lipid a and Nebulizers delivered able inhalation. nanoparticles mRNA powder delivery can mRNA lipid whereas, able convert as forms to to been the In powder efficiency have liquid, by dry of delivered the lipid our forms that antibody. lungs a liquid With properties our dry for antibodies liquid form liquid work inhalation, low nanoparticles form the to delivering ideal the we a nanoparticles. performance are to powders physical delivery lungs. in the powder chemical the making for into powders, converted mRNA of have the These the inhalation multiple monoclonal preserving and on integrity maintaining of aerosol for have monoclonal preparations functionality dry while we successfully partners, while into optimized to them the excellent properties,

studied. We that temperatures or requirements. the found cold and be of being monoclonal room an refrigerated, Thus these have antibodies for antibody properties storage controlled also can depending advantage specific monoclonal the stored on

have and sought We liquid Freezing siRNA and We of Film very liquid to the problem at on that a treat lung functionality Thin the to Freezing control Freezing powders delivery siRNA a siRNA. Thin suspension a room recently was from had Thin protein-based Thin of confirmed opportunity at powders cytokines the We efficiency the nanoparticles. as nebulized to preserving applying or lung dry transformed apply formulate These that chemical the of a inhaled enzymes into can powder, deposition the published The for temperature. patient as administer Film inhalation liquid. lipid Film integrity dry low by when the dry while form Film in powder solid back diseases, to to to administration the stored peer reconstitute paper point-of-use. dry be review to to Freezing also

or storage these have to dry or injection powder their based to distribution. clinical stable immunization chain apply adjuvanted by adjuvanted after vaccines to cold continue as needle not been inhalation. free These point-of-use Film dry successfully Film including because trials Freezing forms currently protein in protein based at intended require used We antigen successful accomplish this. more methods antigen And and preserved; other Thin internasally marketed Freezing been of to is liquid needle-based vaccines their a by directly Thin not during immunogenicity converting powder reconstitution vaccines, has for vaccines form

We liquid also dry a inhaled. activity. forms in stored we're and Film of a recently their of and is of Freezing reported of bio maintain bacteriophages. bacteriophages be the inhalation by have presents low to But The Because bacteriophages solving loss we challenges, its must on presently, using preprint stored application these formulation bacteriophages powders Freezing problem liquid dry are refrigerator one the to aerosols. one. archives, are that in CAGR of for efficacy formulate when to Film powder Thin Thin own administered as bacteriophages Each nebulized and

technology our on well. virus validation vaccines work Lastly, vector is based progressing quite

mucosal cold are lung as inhaled the when by the or chain immunity nebulized deposition, reconstitution needle at for In or as inhalation. directly liquid low injection our after tract, in is required we addressing based by vaccines when powder of views provide work are respiratory internasally injection, of well intramuscular efficiency are the as goal point immunization of storage, administered the and Our vaccines needle free lack to by a this aerosols. as collaborations,

minimal with vector the viruses. have transformed We by suspension Film from vaccines Freezing damage frozen powder form liquid to these to successfully based Thin dry virus

ideal for acknowledge I confirmed aerosol significant colleague, and contributions powder to pulmonary We has his that research want excellent thank properties, delivery. have Professor our to for programs. dry [Indiscernible] our my

for like Lastly, Chief University Texas of and the partnership at over your Chris the you Officer, update I Operating making with company Pharmaceuticals Chris? continued support efforts. its more progress now, call business Cano, the on you development to to Austin. in of the want to and And thank is all the can I'd TFF of collaboration who turn

Chris Cano

you everyone. today. for joining us Thanks, and Bill good afternoon, Thank

are. three TFF on areas As program, team company. for I and areas government three, is the shared, TFF internal development key development partnering the with of growth our have laser two, contracting These three One, previously pipeline growing the pharma business efforts. our focused efforts,

each to key make of strides areas. continue We these great in

existing beyond discussed, Voriconazole Powder, Inhalation Tacrolimus Dale our micro As TFF pipeline expand we including and products, somite. our to Inhalation continue Powder,

antibody joint We Augmenta actively development collaborating the a are now COVID Bioworks. for our on monoclonal of partners, with

new and continue would to The the aggressively TFF development. formulation team that this from value differentiated technology. compounds delivery BD the and and that powder for patients, to TFF have would progress assets, dry products challenges specific that to benefit We payers. generate continues for physicians hunt project stage early And added

addition, everyone working the and former want partnerships update on our I all of we're In to on. collaborations

has very the Williams Dr. As described, is TFF active in mRNA space.

We multiple active mRNA programs underway. have

the We the pharma with large for to partner powder formulating into a their are working dry proprietary directly lung. mRNA delivery TFF

are given the COVID but certain have the applicability of pandemic, corporate TFF powder technology. No not standard We work real partner, are mRNA mRNAs overcome current TFF recently proprietary same, and nature collaborative the is timing to agreement working technology. events pharma also into via lung, do to challenges. the able the of agreed agreements challenges to these formulate Announcing they disclose new mid-cap with vaccine. entered TFFs time Biosciences, order with a events, company, company, of but has their two a feasibility We're new mRNA similar feasibility aspects with an innovative in We and partnership. GreenLight the of delivering mRNA to the our delivery this material directly the to the transfer our dry practice,

removes be current transportation a our for if cold formulation stable seen which have which you COVID of on with working dated as X, storage recent for March Biosciences vaccine powder, more quickly will all, generating dry may challenges not a many, are competitive GreenLight to you reconstituted mRNA faced products. we As announcement site mRNA in and into formulate Therefore, by injection. their chain the

To mRNA on in In second important other the technology Film dry are are discussions play size, we maintains that our knowledge, strongly our of vaccines. We only of programs able powder addition, efficiency our generation engaged in Thin activity has and leading maintains actively of to mRNA will meaningful working the the than the of greater formulating Freezing a and properties, technology we COVID-XX with TFF believe an best vaccine encapsulation are role dry and companies. level we superior aerosol particle formulate the XX% powder an mRNA. mRNA has

VIP working given feasibility as we an treating to COVID By the critically in physicians is value the the for previously staying Dr. TFF a very found events partner Also, of the with disease administration our based trials form antibody route is version file the NeuroRx is is receive mentioned, TFFs trials, in hope announce would patients. offer discussed, of and And nature the Intestinal COVID This Emergency current earlier, stricken alternative these of lung Aviptadil, or synthetic late announcing stage Williams agreed of for project, much standard VIP, to called to powder agreements a Use and TFF it collaborative in COVID in of would space. the TFF pandemic formulating is another Authorization. of naturally on clinical but and results their vasoactive on of has ill ZYESAMI, not practice, patients VIP. product corporate a monoclonal active state are As be tremendous which occurring product space currently candidate Peptide, which the and the a peptide dry patients.

or underway. antibody MAD monoclonal active programs multiple have We

and John of Dr. as TFF our a to Based very vivo working in pleased in closely of successful, formulating step very the As we maintain we pursuing exciting This activity recent generate we next next initial mAbs, are testing. powder XX, Dye supports forward It validates same with very vaccines non-diluted USAMRIID dry clearly vitro the development testing, announce technology to technology of back formulation. USAMRIID, forms mAbs. And the accomplishment. is steps their February on would TFF development. the on development. liquid move in That to seek was able the is that that disclosed of if funding are

a COVID very therapeutic lung. mAbs with on aerosol the while working development be in In mAbs, addition, proprietary agency activity to the levels. government These we maintaining exhibits powder dry to directly as generating delivered that are are another high favourable their properties

formulating pharma with We and currently large engaged to mAbs delivery for are company, proprietary lungs. we also the are their a

preparing round Bioworks. to mAbs joint our out with development continue collaboration testing. we To initial are for arrangement our We in progress vitro Augmenta programs, and

are TFF. VSV provide with peptides, leading cytokines, maintains integrity many discussions are these powder. leading siRNA, and partnerships, companies. DNA, only tremendous we to VSV currently into product their new, collaboration to holds entered technology To vitro and we activity along of AAV molecules. of and dry testing but opportunity form the best where with in achieved. B mAb powder institution are partner’s academic that has collaboration, we agreement superior are formulating complete engaged formulate small formulating updates is to plasmid results properties. knowledge, into This for addition this the antibody We a of with the underway very and actively mAb hope arrangement in to our second a as candidates, recently testing on dry gets In Also, we a our Again, vaccines aerosol our oligonucleotides, other monoclonal programs, we're the able

we to are In at very work partners continue -- closely our addition, we UGA. with

pursuing that the our on are the universal on we influenza results positive announced We October XX. product back candidate protein based advancement of

makers and of projects government which privileged with are over to and and key our of programs the we institutions CIVICs stands protein technology group. were and We numerous our colleagues. Innovation influenza leaders to the to we Collaborative to innovative Vaccine CIVICs academic exciting for present based group candidates share an on. vaccine honored universal are working the We pursuing presented at Last from decision Influenza Centers. agencies. audience included additional participants, XX this University Georgia were We week, opinion

Thin to those Our centres partner, TFF. formulation key assets academic then Film researchers, with and Freezing positioning engage strategy is securing or licensing as transfer and tech the and to

that which are to arrangements, shipped establishes mentioned contract and being our compounds, his partners opening able in these our compounds in Film this opens to agencies testing. different approved Glenn our we TFF These be partnering efforts. formulating Freezing for that In opportunities with, to as partnerships additional and for its Pharma. for for contractor to labs progress an BD have are value We in TFF been Thin this the these the creation Lastly, in more list compounds the are products apply contract, summary, taking pharma partners for with partners collaborating different is very optimize, share In partnering over government proprietary our technology for opportunities on We now and in TFF technology. remarks. these to It team additional making and being We're arena. near we doors TFF tremendous each TFF in future. formulated, and excited government has hope currently growing. dozen arrangement details about of two the tested government

in the partner results, then a partners Upon agreement. vitro these run and powder full Then engage our by viability to animal to collaboration through activity. are activity successful partner testing. licensing First, confirm in specified through testing knockdown in samples testing expect are with our vivo to dry these in a in in by vivo confirm samples we and run blown

it I this have and I think most important opportunity, thank collaborator, partner. valued is While extremely to our

are of and efforts Austin. business the our efforts of University by the development collaboration at All Texas of tireless at these supported partners support

only Thin applications company. the support delivery. With are to continue areas Bill In the we we have technology his and perspective, into BD team, applications of closing, expand growth believe and of a opportunities technology of we very scratched our of Freezing Film innovative the many about the our and the Film research the We drug excited continuing surface of technology. Freezing the from of Thin Williams of new Dr.

at two as that transactions XXXX. have we will confident, repeatedly TFF close signature in said are least We highly development

you for laser hand back I Thank Glenn. We outcome. are to your will on time over accelerating now today. focused it that

Glenn Mattes

a much, Thank there's with you the lot information of that thanks detailed a very for TFF. the Chris. quite excitement in participated rest level and today's presented discuss you The And the you of I excitement call. to feeling of on working share. realized is everyone to today. Well, very TFF day. have every who we team towards sense involved trusted of strong bit a and I the future what is

accelerating and to completed we positive the Today TFF we're making for our the Our while progress internal with positive a formidable set target trials with share and outcomes. build goal product clinical and Tacrolimus up profile is us the pipeline. foundation, you of trials. Voriconazole We TFF confirmed strong meaningful pivotal

strong off a is addition, In the Augmenta is monoclonal of co-development program start, antibodies. to monoclonal as the

time has has our earlier and we update Cano and since current grown were the data GreenLight and to Thin newest ahead In recently strong important activities drug significant. space with have are academia spoke. a announced collaboration company theory with with importantly of Williams colleagues is biologics the moving the with government the business well status at of arena commercialization Freezing week in provider our the Film the last Bill in Chris partners, the and macrophage he a versions PLUS given addition, cannabinoids. The significantly Felix of along we with agreements government. this the truly data development UT tracking on most product NeuroRx, in And discussed agreement pharmaceutical his generated, signed

are signature We on growing development agreements. laser of portfolio focused the

are a on as believe trajectory the of XXXX of in opening achievements steady beginning a are just meaningful call, iceberg. As of company. said tip the the and I XXXX I growth of we the the of the

planted have be the seeds should harvest in soil, We bountiful. great fertile

next investors As call look speaking back the we I will appreciate And forward Operator? to with And always, operator to it we the the quarter. you questions. up and with to open that, support our turn and partners. of

Operator

from comes Jonathan of question Capital first with Partners. Aschoff ROTH Our line

Your line is now open.

Jonathan Aschoff

[Technical guys. Thank Hi Difficulty] I was wondering you.

Glenn Mattes

you Jonathan, we question? that can possibly hear repeat Could barely you.

Jonathan Aschoff

now? Yes. Can you me hear

Glenn Mattes

Yes. much you, Jonathan. better. Thank It's

Jonathan Aschoff

Great. Okay.

with expand So part because how them Why specifics are did cannabinoids you a at give products? PLUS they significant can model? you in the of more and the me fairly any effort about you partner

Glenn Mattes

Thanks Yes. Jonathan. the for question,

So, as by all, have we as the of Connective is that's Capital. run company, Managing Director know, an call, a said who RTR, intermediary Romero, you in I first of Rob

have edibles their that And well we bunch given have either penetration contact science. product, plan formulations of to and this So the great market, through on he products. north that week for penetration the once the very PLUS direct some me get get robust They an in that commercializing. actually, folks a believe PLUS commercial $XXX we significant royalty a is on those and And they They're you facilities. forecasts of $XXX there one as through we or what with produce of very PLUS. doing a sales, expanding And nationally, great PLUS PLUS once We know the in PLUS as are on has out market testing They're speak. expanding great million. is we California, different probably partnerships. almost market has are RTR into PLUS other plan California million, in plan beginning

through going exciting. revenue is be very, endeavor to a lucrative the very future, this RTR, very that meaningful believe and we So very contributor for and a in to very PLUS near TFF

Jonathan Aschoff

outside And Tac. bioequivalence looks my pretty mean, I of could that if data And Thank I get nearly was next about you, approval Glenn. strong. you curious lung. one's

Glenn Mattes

do Okay. To that, answer that answer question to Dale, you can I Christensen? turn it please? Dr. over

Dale Christensen

Glenn. you, Thank Yes.

is dose adjustments each essentially and step is subjects, widely ultimately, exposure there's So they one that back, what take level. subject PK do level, the among possible therapeutic is be varying me matching it a there -- individual it a let reach would drug -- to because

of exposure. with give what so dose And they not show dose so one with an -- equivalent just dose oral equal it's and dose an inhaled a straightforward of that

to BE be So, there's a little more than that required. a normal it would

so to And with the certainly is something that take would are evaluating that get it we there FDA. what

Jonathan Aschoff

me much tell Okay. on Vori anything that see about you that? asthma And I trials. Can the didn't

Glenn Mattes

again. Dale

Dale Christensen

say couple look next enroll completing to no to patients that just Yes. Yes. Thank are I Glenn. and to the months. and can we that we're you, bronchospasm, to-date, forward -- asthma in again, study but, we been subjects study enroll continuing continuing there's the in Ultimately, patients

Glenn Mattes

the for to to et -- the in Tac, caused and in that the a everything we we've that asthma that seen include these far, FDA Thanks twitchy we're able reason quickly and able to data patients IPA trials Just required Voriconazole be supportive we've be Vori pivotal done trial and doing in for see patients we the cetera. have want airways so all Jonathan. clinical of the with bronchospasm is to

Jonathan Aschoff

Thanks Glenn.

Operator

with Ram from Our next comes H.C. question Selvaraju Wainwright.

Boobalan Pachaiyappan

is you this Selvaraju. Ram Can okay? Boobalan in me for dialing Hi, hear

Glenn Mattes

Yes.

Boobalan Pachaiyappan

All right. Awesome.

questions. few So,

and to future. obviously Phase out, you're to asthma start planning start Vori you're X just TFF running the So, for I in trial near a know study

of will not understand two trying the to trials? a be the focus a just and information I'm study? that Phase of So, sort differences are the X between upcoming obtain from you're these asthma sense new planning what similarities study of to what And

Glenn Mattes

spoke, and in said can trial decided that just I Dale them as asthma powder Phase patients sure study include in of run in to the looking the at we as X for TFF trial. So we a the at to urging FDA be the

population a this to is So, the way enhance the of patient trial. next

Boobalan Pachaiyappan

specific Okay, all how this right. will study, upcoming Phase importance? what Thanks. given And success do X the with to metrics study? you define be in And respect

Glenn Mattes

better see mean So at power powered we be non-inferiority mine the that adverse trial the will efficacy. event for the better and will efficacy, be data we for profile. but non-inferiority don't will doesn't a pure and efficacy, expect This and to -- and efficacy,

Boobalan Pachaiyappan

Okay.

the challenges? this But route? delivering non-lung respect for to with lung challenges during And anticipate indications. lungs to such what rational drugs possible for one is treating kidney the disease? what Tac, the your as what So, to treating So, we with attack indications potentially on delivering these TFF ways the kind lungs are again understand to of like, could so to respect breath

Glenn Mattes

give answer other to I like to a you a the Thank I'd Dale, could people you. have of brief and questions. then move lot queue. on in

Dale Christensen

Yes.

is meal, eating briefly, because very soluble soluble. fat Tacrolimus somebody water a and fat absorbed high not based they high it's widely if in someone it on So, poorly eat is bioavailability meal, fat has differential a if

also There And drugs it are on Tarcrolimus other wide in orally. variations based GI taken so in are tract. bioavailability, stays the that

interaction defined, all would that when a gastrointestinal, a it's that And single given via from you that drug interactions of bypass dose. the you PK there, or gives so, and more lung, tighter occur from a dose delivered range the

in to think the will in the advantage. balancing lung versus the advantages the any ultimately, toxicity the versus we and lung. that's levels toxicity gained so be safety for for be going it localised potential And lung by that, And potential any system or,

studies. addressing we're toxicology from that So our

Glenn Mattes

you. happy I Thank be will to…

Boobalan Pachaiyappan

right. All

Glenn Mattes

… to line. talk just sure more other and I want calls. be on that questioners we Boobalan the some further you to on get

Boobalan Pachaiyappan

right. All

Glenn Mattes

much so your for understanding. you thank So,

Operator

Mayank Our with from Mamtani comes Riley next Securities. question B.

Mayank Mamtani

Hi. Good progress. on afternoon, team. the Congrats

government friends many the new thanks today contract and So I and update. the for question. announced appreciated the comprehensive

great effective the with curious starting a FDA Dale dose. if you maybe, want I'm also versus lowest can higher here, So about see just to so pursue you you a like go think XXmg. dose XXmg, therapeutic when with to dialogue, they

A in lot answer, So arms in we're study? in pivotal would can your in words, a are have there your - other the folks we of have again, you a if two brief Dale, different queue. out time. just those running of And

Dale Christensen

induce want be doesn't the of that toxicity, that But question. highest infective, you resistance. they at ultimately, can for so dose the tolerated potential Good development to for avoid anti Yes. you

no go efficacious develop. to dose, you where minimally that's a And requirement there's resistance would to because see so,

Mayank Mamtani

player. getting partnerships inflection doing one mRNA. different to think a last And about, just you Understood. provide? Any said you're trying an the that partnership on in the these progressing of that publication maybe quickly also Chris, of of a in for modality? meaningful the, I'm Also you the with of is kind then, RNA, update, kind had that a kind XX top a siRNA there the think visualise light modality curious, update, was work, and, lot to I obviously work -- on had should we front of How could you point? of a

Glenn Mattes

Chris, answer can you that?

Chris Cano

And Glenn. the sure. Yes, for question, Mayank. Thanks, thanks

excited our work. really we're So about

mentioned, top And Pharma we speak, company. you did work As XX quarter, a that last continues. about

shared a I've process, As everyone, right. with it's

very it And vivo, does continues the in that vitro, received optimising the materials, well. partnership materials, pursue so formulating when to continuing we're so we in and time, take that

as I partners. over we're with XX different earlier dealing well had mentioned, As

to in do our my that goal. flowing on two obviously I'm year. And expect And That's I goal. successfully transactions And our exceeding everyone at least pipeline. this so closed signature we we're comments, focused as to laser

Glenn Mattes

add I that. just brief on could color a Mayank,

Mayank Mamtani

Go ahead.

Glenn Mattes

listeners want can understand, the keep this really outstanding all the really jobs the I another with the want doing have experimentation. we're have go. track everything we're very we're are want, of they working with companies, to all we coming at. office is only of experiments back with. so to whiteboard come end way bigger do. on But out of data of the steadily And supportive, big these moving that many And where the really we're round they'll very they towards that's we the we where us companies With data, positive, my in

the so tip the So, we the they We're will get already. this -- we, of these much anybody, finish want than the line, know get we've moving to to line. more done things iceberg. is at finish just And to

close think getting very I and we're --

Mayank Mamtani

Okay.

in really on with I I color -- push have how and many CDAs I'll do another appreciate have Just and maybe us. you you place. respect, the Glenn, time, But we Bill NDAs to want

Bill, Because point different stability quickly, And Just at could might some from, chain and share mRNA? you it stability approved? standpoint very as -- Film immunity. kind we benefit, immunity, you maybe any data on cold when maybe that? Could and And on also other versus you again, you looking lyophilization about all? important color, transmission vaccine mucosal Thin tested about any sterilizing this storage I think but for be may, can if think I'm based you investors, if color of just not mRNA about a to that qualitative comment protein how also,

Bill Williams

Mayank. Thanks, Excellent yes. question. Yes,

directly first So mRNA of my looked COVID. lab, recently that for vaccines are the for one in research time for have the emergency two use we've I at approved

one maintained powder those powder with has dry So I lyophilization. encapsulation It mRNA and our comparison vaccines lipid of been the from And Film have at dry now. and as Freezing temperature of several a Thin that done looked to-date powder at a for the conventional we've side a produced nanoparticle. those vaccines side by pre-freezing, weeks the actually stable room

to was original So nanometer was produce able particle to process -- that compared able the and that -- size not not conventional we reconstitution. and upon lyophilization this we've done where

immunity. especially of designed So highly to with they've one that then yes, vaccines several mRNA are we're of the in with, works guards Freezing lung -- nanoparticle nanoparticles; dry now. delivering, not for particular their And that's powder if lipid I not Film inhalation, lipid -- conventional lipid that Thin it's lyophilization the with partners right mRNA with again, their could modality, they a inhalation, nanoparticle to am approved happened to they mucosal for powder the inhalation. for amenable work even confident couldn't two working COVID And mRNA

Film Freezing working for those and So is Thin applications. it's

question, Mayank. good really your answered that hopefully, So,

Mayank Mamtani

about -- And

Glenn Mattes

Mayank, we and way, you. Q move of the by line to Thank …. catching of – have all a questions, up can way you on we on the always other

Glenn Mattes

All you of line, line the will we the you questions. on as long as on have stay

all that we're So the interested you're about fact have in so excited here. questions

So clock we're looking here. the not at

Operator

comes Our with next question from Jason McCarthy Group. Maxim

Unidentified Analyst

the Quintavalla Jason taking McCarthy. Michael is this Thanks for on question. Hi, for the [ph] line

studies to a just I'll sizes can so on So especially we heading I time, year. pivotal studies gave keep us this it like color any as on at Tac, as another kind figure late towards the trial we the and Vori back up those always this troll time. for are coming of we're on early of circle needed But as

Glenn Mattes

was going a zero help the patients, out what all really run give last with view conducting pretty know looking Jason soon the we more as had Yeah. waiting notable XXX some of we've protocols tell time at advisory those meet we is number receiving we for upon been we've specific little so pivotal them. got been this investigators and public to us report Tac final as let But Vori thinking along. the will if and the those Vori you and you first to agency If we we were I that to numbers. look, our trials. I to in in, some the with pivotal the can, Well, of I report, analyzing at have we'll those which consistent mean, on with us not the are trials. boards about by patients Based craft with you

Unidentified Analyst

All more more subcontractor to government would you then I'd been right. and bit detail. see Thank mind, if allows more, greater just you if before? What that what one that US to license in exactly difficult And like have discuss that do with you. could means just don't you a the

Glenn Mattes

this asked opportunity, tell asked are excited you -- hope Well, you be we really glad this really about can what able really we're glad government and into doing here. we're Because detail had information hear that question. I'm go on you to we I waiting feels classified great just is. that to this kickoff yesterday unbelievably a meeting to so that We agency how

we're understand only diligence to allow compared We based talking as of some started work in can incredible And to honestly, and formulators. is can and at of the this alluded announcement. process probably the year where inhalation formulations I you the the you What the to formulations government an intranasal in to lungs, a other we at on arena, conversation. look an not potential but a potential Almost are we make other through you went contractor. a So position that primary government to almost eye. were with coming his also to and to a given half really contract to on topical and and -- I mercy agency contractor of the subcontractors, the us ago, we we've the tell to one-on-one specific

So what at We systemically does now the a But one, up we government. do this financial opportunity. for can't Number be the to disclose contractor point. this to terms set systematically are -- great TFF?

talking been how we with experienced work very working the this here -- we're arena. know potential is we've to to organized internally, we're system, the contractor government So other opportunities, we've in

call, although only in really all be can't we our of a our partnerships. of what's terms of arena, outreach as I investors hope like that about to and So open and in for here, all really appreciate all this be we'd that listening opportunities, the government significant the to not happened but are the

we've and is. I on you and say to it just asked, how great can going I to team, is work unless So wasn't a what of voice testament hope this done and our this, in disruptive position technology what behalf and hear tremendous

Unidentified Analyst

Lots of Thanks taking stuff. questions. for the exciting

Glenn Mattes

for Yeah. Thank so the you much question.

Operator

with TW Research Carlson from Our next question comes Daniel Group.

Daniel Carlson

quick for my try guys, Hey, question. thanks run time. to I’ll over taking and be early

Regarding dosage activity. confidence good be What gives you've an into seeing -- you formulation? seem inhalable mRNA, to RNA you modalities, et the you're cetera can RNA that siRNA, formulate

Glenn Mattes

Daniel? for answer you could Williams it Dr.

Bill Williams

Great Hey, question. Sure. Daniel.

our nanoparticle to research Film a minute group the two lipid one with lipid the used in mRNA the from have research recently, in COVID-XX I with we different different experienced vaccines. partners. fortunately, probably ago, group, work Freezing -- So, Thin formulations And technology five I've nanoparticle of approved most directly mentioned we've mRNA

and have the powders amenable characteristics that inhale by delivery are to inhalation. so produced And powder we dry they characterized have those, from those powder

know we it lipid its and focus it do done. So on can we've the of use be what presents validation done Thanks each of coming, coming on own is best for to the individual studies, And that's it, technology we parameters, mRNA different we properties. nanoparticles that's up a question. And what approach we're the what our -- part one. that's with unique the each composition

Glenn Mattes

if I add to any Day, a we have Daniel, or late will but TFF Science before, we're looking early June. questions, sometime thing other have want you One at in May

in we'll picking point, the more time be as, at that mature data, we're So academic more some more space. is announcing partnerships have reason that the and that maybe and we'll some

I'm tuned on announcement others. a There are to specific So sorry interrupt. Daniel stay for that.

Operator

Morrison Our next Bill Securities. with from question National comes

Bill Morrison

can, or I'm in on. I partners write did the there -- than of lots you taking couple But fast biologics, for greater say was biologics of thanks guys, Hi, questions. as dozen small to a XX molecules? and good going both stuff trying

Glenn Mattes

Hope to Bill, from you're doing you. Hi, hear good well. Yeah.

materials it's to XX. of a trying just, do mRNA, different count really without in the their working us think sort some probably are of mentioned They company on us SRNA, for to now we're revenue good a specifics vaccines, of the let term we entity I fact, Chris of, do that chemical from we’re monoclonal, in we quite time. of have He asked new of companies doing GMP we north VSV was a partners, actually And with actually five one formulation, on. first phages, top three where giving they've not some mentioned, for working are their they vivo hope peptoids, just offering the plays, transaction couple that's actually did So work testing, use experience for will in opportunities won't name we're yet. But job that of manufacturing. near the specifically, compounds, graph we

it's each So it of doing don't and every XX XX. Bill, we XX, it kind and XX, above. just understand next in the this categories. say week week think really to going keep kind of to want stands And grows you week I of We're

So is is But funnel, we having Chris to some chuckling full not check funnel in the on numbers. a bad on because erase and he probably we're names. whiteboard, really the comes ourselves

And so far we haven't raised any, we just names. keep adding

the So But you of that juggling we're seven doing one It's what [Indiscernible] was like plates it's know it's unbelievable. ever don't kind here. guy at saw if and time fun. -- I

Bill Morrison

update seems on so. just the then any upfront? it UNION, Yes, And on

Glenn Mattes

Yeah.

inhuman trial Bill are be and of that Dale triggered initiating. and by is going So upfront mentioned those the trials our conclusion the first to

would look latter in definitive of I the year. for the here So part something

Bill Morrison

Great Beautiful. job. guys. Thanks,

Glenn Mattes

Thanks, Bill.

Operator

comes Dick question from with Williams [ph] next Williams our So Resource.

Unidentified Analyst

I well on year. guys prior say this a have but phenomenal team you more done that as is your Hi, to wonderful firstly I times guys times. medical current professionals the year-to-date job Glenn. to the know annual, I'm as like was and But you interested and have congratulations job. in the you done I'd last in a

the of one a don't the that and or thing hit one ran marketplace disappointed ago, So we part the the day have XX%, marketplace a of are that I last of just course, but in sector, announced biotech been we took the I'm out that. itself that of I last two to investors and of we weeks it guess, in I what a results and favor, biotech And of sector with significant, our the microcap was were so, in have lot just have know with the question. in stock all were And sure out. realize

with just But So we made of have announcement kinds NeuroRx to those wanted relate yesterday. the live I and you things. to to

very unnoticed, this was I went in some totally significant. think because there there was things that felt I

be in process think a of that norm wrong that not thereafter. probably And a occurs management have And the the talked this in with biological and doing companies. trial this I'm close, and plots cytokine pronounce particular we're XX release, superb. extremely to and to that product and ZYESAMI. else for what this important. is with in name fine. of going day something the of But COVID that FDA I of that achieving cell lot They're the about controls big the for oxygen/blood endpoint our is Firstly, that's cell opportunity a the of to level what very high They in And is dictated we what they're the should to with executives them the achieve gets the that's I from we very, forget do and with body it's damaged company one are team pharma very pipeline. that, whatever them

many in than they trial. have And were achieved currently early good. thought achieve that that in have the were XX A, continue trial I more they with it are the and that discovering don't starting they started results; they people would this But success on they to And would it. know to were So days. to how be beyond

hey, back and to So in with this XX the went them a last days. XX endpoint, and FDA to should the the they several really agreed XX guys, the extended it and endpoint, a be days, said, not day FDA day

if in a they obviously, is fit how to there can that So drug, determine in the to be that how that authorization FDA. quickly some an doing to to of trial. that use extension an you to ready end we from with my But assuming we're color results can or ask we add days for trial are if could it question can and the particular as XX determine applicable it how powder be emergency used at we

And this if fit that all? is, is? does how at So my question how we close anyone all into appreciate

Glenn Mattes

of all, you the Okay, for question. thank first

so you've understanding transaction for bringing company. fully Chris this. RX an for done why of it this such new credit so closest He much we're both great think was forward. the important gets job to -- the I a and is the

have want been I work take the definitely would early the would ability on situation the just less it real wouldn't appreciation still comment analogous about really earlier before you you which grasp to did Cano, this on question. be build remdesivir but of about, is into some that you that hope I this know with patients, Chris is think is the on very value been a we Chris the do, your a comment COVID so wondering - have I product to we're to So guess different to is please? clear I close. here. you curious severe we This are could effective,

Chris Cano

for your Dick comes to it. thank you question thank the support. for And we're about When neuro RX, excited and absolutely. really you it Yeah,

You know, really being they're treating critically frisking deliver right Right able exciting it is to formulate to now us, patients, for right. as right? treat a and ill COVID dry patients that powder

if viewed, in create so can always powder, And or disease treat dry state. patients earlier sickness the we we can a we've

This second I'll view work. -- product. goal at of generation kind their that the is this lead is So it of lead you're really correct be a asset. going we're to just their line, this call -- And it as I still doing there feasibility

question So your hopefully, I satisfactorily. addressed

Unidentified Analyst

add end obviously to come we it they're day the to on at it's so involved to Okay, essence secondary later can't they're file a days or be Because be window. EUA in date. be for won't, out with XX the But going at – if a and that in we it in product the works, a XX product approved going of would

Glenn Mattes

think would We right behind the it. be follow-on that

we the these come can on will with to of powder probably be be a around sort some existing be to FDA done. And a transitions we've still of product this the So, and – Dale to they'll would terrific the in thinking lot, through, of able – version, experience have clinical quickly discussions the another pre-ground, toxicity to need lot work got word And how amount know the from here. lot will – it on then But some determined. exciting arena is some us. to on do but is But word for a the comment, be I work. use we the have to you find a bridging of opportunity very

Unidentified Analyst

answer exciting. the able thanks for use that. to I'll to Well, word I'm do that. the And

think it a gave looking that that deal. I I for, It's and you color was terrific. on congratulations

Glenn Mattes

Thanks.

Operator

Our Investor. from Steven next [ph], question Private comes Glassman

Glenn Mattes

guess, I wrong, your name Steve.

Unidentified Analyst

the you strategy Glenn, work flu doing What's on there? okay. the talk monetizing how can plan universal vaccine? on you That's about the you're

Glenn Mattes

Sure.

with partner caucus, them we're those these right? the forward. flu TFF. all and bake-off two will to can into work tie you one and development. So, a flu be we're kind then individual the commercial to And those take detect do if in will of universal leading those as take bring as able what find developed, funding find non-dilutive hoping Steven, will than they a are vaccine academic we we institutions flu emerge, be then be becomes, Steve, transfers emerge can that to the leading from of the is up doing, hope then And it engaged of a or researchers to potential imagine academic forward as to the to vaccines possibly more or antigens beauty further as vaccine, we or to likely And

Dr. until a technology us have data generated. word to on Ted I is by participants we UGA line institution to Ross, sort you to be, we first and purpose are is know, ubiquitous of think that are announce XX partnering will trying really we second enabled just was Dale the again, on around – and internal policy the which the we're gave, let civics actually us, this presented, there not will material was Bill working with agreed their work we're academic presentation So we a this where the presented of going and that and that where at expose, John do

there Rushmore, months Mount that's are on universal and flu And institutions you interested. have then if to others will, hope away. are are them So vaccine. the two two other of actually we academic that that engagements Researchers, with

monetizing have those and have high through we done getting So think transfer, them in we partnerships. financing then the non-dilutive we're a a likelihood once of

Unidentified Analyst

a that's big XXX million this very country opportunity. year doses in per

Glenn Mattes

new Well, yes, with especially vaccine.

Unidentified Analyst

Exactly. take young Yeah. less we'll plus, be because it a a people so tripod more Yes, as much resistance. be was old children well it'll more way it frail ubiquitous young, injury, effective

Glenn Mattes

number at all they about need to -- needleless of access vaccine there's you a Steve reasons, if Right? to for reconstituted especially, all, refrigerated. place in know, think powder and vaccines. if the any parts And have where the plays, the place vaccines world may ability either the be can't, So this Cold that to any Chain technology is bypass or

So, are. you because to it how us know, coming I opportunity am these these just glad really big gives questions are talk about an opportunities

Unidentified Analyst

now I’ll use and exciting, Very word. that

Glenn Mattes

Okay.

Unidentified Analyst

I problems adverse in reactions? in there any any the VIVO, trials inhaling for Has if powder, Dale, been for Question may. human substances,

Dale Christensen

is Thanks, [indiscernible]. That question. good a

far has have patients the of been board, general the reported most due drops the in and no and there inhale. to appears seem some have, practice. or Voriconazole, are been few you of of a following be there for reports important, that experiences ability a this either adverse our goes in lightheadedness an -- indicative clinical costs more costs But is have That of and the few effect that normals there mild of healthy patients all headache, asthma of likely that Tacrolimus and FEVX inhalation inhalation bronchospasm the or experienced know, to in for even of induction no lung. -- on in both trials, either that and Voriconazole, to Tacrolimus the So to -- in across that's

So all to-date has function patients, testing in trials, all as shown that healthy normals been any well there's abnormalities. as pulmonary no

Unidentified Analyst

Thank Dale. Excellent. Thank everybody. you, you,

Dale Christensen

Welcome.

Operator

follow-up have from Group. We up question line Daniel TW Research with Carlson

Daniel Carlson

Bill programs, COVID you internal follow-up just the to that I Dr. there's competitive on know Do see this? any technology Hi. Yes. is TFF there. being on vaccines. with out other technologies other there's

Bill Williams

liquid work question back as of. for injection freezing I'm earlier, point too to the for the that to for a lawfulisation process. is products, No. the it's lawfulisation of conventional [ph] slow, inhalation, it's Not I a end these But at I of conventional at a aware a mentioned product the and day reconstitution will lot for of if whether use. mean,

That's get because And understand our that. comparison of of like our And which mRNA. to the that's degradation a studies. damage in we're do that's causes the that lipid nanoparticle, to control finding the data we you type our so -- that to

great. yes, So,

Daniel Carlson

could more one if just Gentlemen, question. follow-up I

one vaccines. if going own? with wondering run You that MTA vaccines done, of said under was if have the was I'm an just you it your COVID the as done can? out did or Remdesivir, that getting on you and If you

Glenn Mattes

researcher. all that Daniel. Still Yes, I That's I'll point. as it answer a ran say at this can

Daniel Carlson

Thanks, it. Okay. progress. guys. Appreciate Great

Paul Sagan

Yes. Thank you.

Operator

That concludes today's call question-and-answer Mattes like closing remarks. back Glenn turn for I’d the session. to to

Glenn Mattes

on for with the that of for greatly call, Well, stayed it's entire appreciated. us you all have

of accessible, For love me, who about you know me, accessible. know we I'm that highly doing those talk what to we'd we're to are questions. and your -- here. of we're love Those don't you answer very We'd

you all we thank a very and move much. on support. you So forward forward. look Thank progress and well hope well our your we as you stay you I updating for to

Operator

this call. gentlemen, concludes conference Ladies participating. Thank you and for today's

disconnect. You may now

TFF Pharmaceuticals (TFFP) 11 Mar 212020 Q4 Earnings call transcript